Powder Or Dust Containing Patents (Class 424/46)
-
Patent number: 10471118Abstract: A pharmaceutical composition includes a retinylamine derivative having the following formula (I): where R1 is an amino acid residue, a dipeptide or a tripeptide that is linked to the retinylamine by an amide bond.Type: GrantFiled: June 1, 2015Date of Patent: November 12, 2019Assignee: CASE WESTERN RESERVE UNIVERSITYInventors: Krzysztof Palczewski, Zheng-Rong Lu
-
Patent number: 10420722Abstract: Dry powder vancomycin compositions and methods for administering and preparing such compositions are provided.Type: GrantFiled: December 10, 2015Date of Patent: September 24, 2019Assignee: SAVARA INC.Inventors: John Lord, Jaakko Taneli Jouhikainen, Herman E. Snyder, Pravin Soni, Mei-Chang Kuo
-
Patent number: 10406171Abstract: The present invention is synergistic antibiotic compositions having pH adjusted profiles for manufacturing combination, and administration, particularly for patients at risk or suffering from ventilator-associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis. Antibiotic compositions containing fosfomycin and aminoglycosides having individually predetermined and selected pH ranges are manufactured and stored for in combination prior to aerosolization, preferably with a specially designed in-line nebulizer attached to a ventilator.Type: GrantFiled: November 7, 2016Date of Patent: September 10, 2019Assignee: SAVARA INC.Inventor: Alan Bruce Montgomery
-
Patent number: 10359175Abstract: The present application relates to a light-emitting film, a method of manufacturing the same, a lighting device and a display device. The present application may provide a light-emitting film capable of providing a lighting device having excellent color purity and efficiency and an excellent color characteristic. The characteristics of the light-emitting film of the present application may be stably and excellently maintained for a long time. The light-emitting film of the present application may be used for various uses including photovoltaic applications, an optical filter or an optical converter, as well as various lighting devices.Type: GrantFiled: August 13, 2015Date of Patent: July 23, 2019Assignee: LG CHEM, LTD.Inventors: Tae Gyun Kwon, Moon Soo Park, Su Young Ryu
-
Patent number: 10286065Abstract: Embodiments are directed to compositions and methods for treating viral infections.Type: GrantFiled: September 21, 2015Date of Patent: May 14, 2019Assignees: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, BAYLOR COLLEGE OF MEDICINE, PULMOTECT, INC.Inventors: Burton Dickey, Scott Evans, Brian Gilbert, Diane Markesich, Brenton Scott, Michael Tuvim
-
Patent number: 10265293Abstract: Oral cannabinoid formulations, including an aqueous-based oral dronabinol solution, that are stable at room or refrigerated temperatures and may possess improved in vivo absorption profiles with faster onset and lower inter-subject variability.Type: GrantFiled: April 19, 2016Date of Patent: April 23, 2019Assignee: INSYS DEVELOPMENT COMPANY, INC.Inventors: Venkat R. Goskonda, Ashok Chavan, Amit Kokate, Howard Gill
-
Patent number: 10219613Abstract: A method of magnetically induced removal of hair from a brush, wherein the method is comprised of the steps of applying a ferrofluid composition onto a portion of a user's hair; brushing the ferrofluid composition coated hair with a hair brush having a plurality of bristles; placing a magnetized hair brush base having a plurality of openings over the bristles such that the plurality of openings aligns with and interacts with the plurality of bristles such that substantially any of the user's hair that is located within the bristles is attracted towards the magnetized hair brush base; and removing the user's hair from the bristles.Type: GrantFiled: April 17, 2016Date of Patent: March 5, 2019Inventor: Vidhyasai Annem
-
Patent number: 10195149Abstract: The present invention relates to a continuous process for preparing microspheres and microspheres prepared thereby, and in particular, a process for preparing microspheres comprising steps of injecting a first emulsion and a second emulsion at the same time to form microspheres instantaneously, applying high pressure to the microspheres formed, and injecting the microspheres into an agitator, wherein the steps can be carried out continuously, and microspheres prepared thereby. When microspheres are prepared using the method of the present invention, scale variables, which have been the biggest disadvantage in existing preparation methods of microspheres, can be significantly reduced, drug encapsulation efficiency can be improved, and small and uniform particles can be obtained.Type: GrantFiled: May 15, 2014Date of Patent: February 5, 2019Assignee: CJ HEALTHCARE CORPORATIONInventors: Yi Mi Kim, Sun Kyung Lim, Mi Ran Park, Young Joon Park, Seung Hee Baek, Hyun Woo Shin
-
Patent number: 10188614Abstract: The present invention relates to active substances in particulate form, to methods for preparing them and to their uses. The present invention provides particulate powders, such as might be of use for delivery using a dry powder inhaler (DPI) or similar delivery device, having properties which may be beneficial to the DPI delivery process.Type: GrantFiled: June 9, 2017Date of Patent: January 29, 2019Assignee: Nektar TherapeuticsInventors: Peter York, Boris Yu Shekunov, Mahboob Ur Rehman, Jane Catherine Feeley
-
Patent number: 10188612Abstract: The invention provides microparticles for use in a pharmaceutical composition for pulmonary administration, each microparticle comprising a particle of an active substance having, on its surface, particles of a hydrophobic material suitable for delaying the dissolution of the active substance. The invention also provides a method for making the microparticles.Type: GrantFiled: November 20, 2014Date of Patent: January 29, 2019Assignee: Vectura LimitedInventors: John Nicholas Staniforth, Haggis Harris, David Alexander Vodden Morton, Robin Bannister
-
Patent number: 10172773Abstract: Disclosed is a method of reducing or avoiding staining in or on clothing caused by a cosmetic or dermatological preparation comprising one or more antiperspirant substances and/or of improving the ability of stains in or on clothing which are caused at least in part by said preparation to be washed out from the clothing. The method comprises including in the preparation one or more cationic surfactants.Type: GrantFiled: November 6, 2013Date of Patent: January 8, 2019Assignee: Beiersdorf AGInventors: Michael Urban, Heike Miertsch, Stefan Biel, Sabine Kuehne, Stefan Bruening, Rolf Kawa
-
Patent number: 10159645Abstract: Aerosol formulations comprising glycopyrronium bromide in combination with formoterol are useful for the prevention or treatment of chronic obstructive pulmonary disease. The formulation further comprises a HFA propellant, a co-solvent, and an amount of inorganic acid sufficient to stabilize both the glycopyrronium bromide and the formoterol components. Optionally the formulation may further comprise beclometasone dipropionate.Type: GrantFiled: July 29, 2015Date of Patent: December 25, 2018Assignee: CHIESI FARMACEUTICI S.p.A.Inventors: Sauro Bonelli, Francesca Usberti, Enrico Zambelli
-
Patent number: 10119135Abstract: The present invention relates to the identification of microRNAs of the miR-148 family that are involved in the pathogenesis of chronic pulmonary diseases. The present invention relates to micro RNA of the miR-148 family selected from miR-148a, miR-148b and miR-152 for use in the diagnosis, prognosis, prevention and/or therapy of a chronic pulmonary disease. The present invention further relates to miR-148 inhibitors, pharmaceutical compositions comprising such inhibitors, their use in preventing and/or treating chronic pulmonary diseases, and methods for preventing and/or treating chronic pulmonary diseases. The present invention further relates to transgenic, non-human mammals and methods for identifying modulators of miR-148 and methods for diagnosis and/or prognosis of chronic pulmonary diseases.Type: GrantFiled: May 15, 2013Date of Patent: November 6, 2018Assignee: RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERGInventors: Marcus Mall, Raman Agrawal, Martina Muckenthaler
-
Patent number: 10105300Abstract: Disclosed is cosmetic or dermatological preparation which is present as an aerosol spray and comprises one or more antiperspirant substances and one or more cationic surfactants.Type: GrantFiled: November 6, 2013Date of Patent: October 23, 2018Assignee: BEIERSDORF AGInventors: Michael Urban, Heike Miertsch, Stefan Biel, Sabine Kuehne, Stefan Bruening, Rolf Kawa
-
Patent number: 10092512Abstract: The present invention includes compositions and methods for treating and delivering medicinal formulations using an inhaler. The composition includes a space filled flocculated suspension having one or more flocculated particles of one or more active agents and a hydrofluoroalkane propellant. A portion of the one or more flocculated particles is templated by the formation of hydrofluoroalkane droplets upon atomization and the templated floc compacts upon the evaporation of the hydrofluoroalkane propellant to form a porous particle for deep lung delivery.Type: GrantFiled: May 12, 2010Date of Patent: October 9, 2018Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Keith P. Johnston, Joshua Engstrom, Jasmine Rowe, Alan B. Watts, Robert O. Williams, III
-
Patent number: 10092557Abstract: A nimodipine injection concentrate and diluted formulation comprises nimodipine (base or salt), an effective amount of a hydrophilic surfactant, and a pharmaceutically acceptable carrier for injection which is an aqueous solution, an organic solvent, an oil, or a cyclodextrin, such that the nimodipine is substantially contained in a concentrated injection solution, suspension, emulsion or complex as a micelle or a colloidal particle or an inclusion complex and the formulation is stable and clear. In certain embodiments, the hydrophilic surfactant is polysorbate 80.Type: GrantFiled: April 12, 2017Date of Patent: October 9, 2018Assignee: Nortic Holdings Inc.Inventors: S. George Kottayil, Amresh Kumar, Prasanna Sunthankar, Vimal Kavuru
-
Patent number: 10081060Abstract: A method of reducing silver(I) salts to silver nanoparticles employing a carbohydrate reductant in the presence of an inorganic base, a surfactant and optionally a polymer. The method is performed in an aqueous solution at a temperature up to 60° C. and for a duration of up to 40 minutes.Type: GrantFiled: March 9, 2016Date of Patent: September 25, 2018Assignee: King Abdulaziz UniversityInventors: Hassan Amroun Ewais, Iqbal Mohamed Ismail
-
Patent number: 10022323Abstract: The present invention concerns a method for making an inhaled pharmaceutical composition with improved powder handling properties comprising a stearate, a method of preparing such a composition, and the use of such a stearate in a composition when dispensed into a receptacle for use in a dry powder inhaler receptacle.Type: GrantFiled: March 28, 2014Date of Patent: July 17, 2018Assignee: VECTURA LIMITEDInventor: Matthew Green
-
Patent number: 10020807Abstract: Reduction/oxidation reagents have been found to be effective to chemically cure a sparse metal nanowire film into a fused metal nanostructured network through evidently a ripening type process. The resulting fused network can provide desirable low sheet resistances while maintaining good optical transparency. The transparent conductive films can be effectively applied as a single conductive ink or through sequential forming of a metal nanowire film with the subsequent addition of a fusing agent. The fused metal nanowire films can be effectively patterned, and the patterned films can be useful in devices, such as touch sensors.Type: GrantFiled: February 26, 2013Date of Patent: July 10, 2018Assignee: C3NANO INC.Inventors: Ajay Virkar, Xiqiang Yang, Ying-Syi Li, Dennis McKean, Melburne C. LeMieux
-
Patent number: 10004690Abstract: The present invention provides administrable microparticles in vivo through a medical conduit, a composition comprising the same, and a manufacturing method therefor. The microparticles of the present invention have an advantage that a clogging phenomenon does not occur for an endoscopic administration through a spray apparatus.Type: GrantFiled: January 21, 2015Date of Patent: June 26, 2018Assignee: UTAH-INHA DDS & ADVANCED THERAPEUTICS RESEARCH CENTERInventors: Eunhye Lee, Keun Su Kim, Don Haeng Lee, Young Hwan Park
-
Patent number: 9855212Abstract: Embodiments of the invention relate generally to formulations comprising dimethylsulfoxide (DMSO) alone or in combination with methylsulfonylmethane (MSM), and one or more therapeutic agents, and uses of such formulations to treat infectious diseases. In several embodiments, such formulations are effective in treating drug-resistant infectious diseases, for example, drug-resistant tuberculosis.Type: GrantFiled: October 29, 2010Date of Patent: January 2, 2018Assignee: Abela Pharmaceuticals, Inc.Inventors: Colette Cozean, Rodney Benjamin, Anthony Keller, Jeff Varelman
-
Patent number: 9761771Abstract: The present application relates to a light-emitting film, a method of manufacturing the same, a lighting device and a display device. The present application may provide a light-emitting film capable of providing a lighting device having excellent color purity and efficiency and an excellent color characteristic. The characteristics of the light-emitting film of the present application may be stably and excellently maintained for a long time. The light-emitting film of the present application may be used for various uses including photovoltaic applications, an optical filter or an optical converter, as well as various lighting devices.Type: GrantFiled: August 13, 2015Date of Patent: September 12, 2017Assignee: LG CHEM, LTD.Inventors: Tae Gyun Kwon, Su Young Ryu, Moon Soo Park, Seong Min Lee
-
Patent number: 9750789Abstract: The present invention provides a method for treating a subject suffering from tuberculosis which comprises administering to the subject a composition comprising an amount of an inhibitor of a matrix metalloproteinase (MMP) in an amount effective to treat the subject, such that the therapeutic effect of said composition is different than the therapeutic effect attributable to the antibiotic properties of said composition. The present invention also provides a method for reducing or inhibiting destruction of lung extracellular matrix in a subject comprising administering to the subject at risk for such destruction a composition comprising an amount of an inhibitor of a matrix metalloproteinase (MMP) in an amount effective to reduce or inhibit destruction of lung extracellular matrix in the subject.Type: GrantFiled: February 17, 2012Date of Patent: September 5, 2017Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Jeanine D'armiento, Paul Elkington, Jon S. Friedland
-
Patent number: 9738780Abstract: Zwitterionic crosslinking agents, crosslinked zwitterionic hydrogels prepared from copolymerization of zwitterionic monomers with the zwitterionic crosslinking agent, methods for making crosslinked zwitterionic hydrogels, and devices that include and methods that use the crosslinked zwitterionic hydrogels.Type: GrantFiled: July 15, 2016Date of Patent: August 22, 2017Assignee: University of Washington through its Center for CommercializationInventors: Shaoyi Jiang, Hong Xue, Wei Yang, Louisa R. Carr
-
Patent number: 9724344Abstract: Inhalable compositions are described. The inhalable compositions comprise one or more respirable aggregates, the respirable aggregates comprising one or more poorly water soluble active agents, wherein at least one of the active agents reaches a maximum lung concentration (Cmax) of at least about 0.25 ?g/gram of lung tissue and remains at such concentration for a period of at least one hour after being delivered to the lung. Methods for making such compositions and methods for using such compositions are also disclosed.Type: GrantFiled: May 15, 2015Date of Patent: August 8, 2017Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: James E. Hitt, True L. Rogers, Brian D. Scherzer, Ian B. Gillespie, Paula C. Garcia, Nicholas S. Beck, Christopher J. Tucker, Timothy J. Young, David A. Hayes, Robert O. Williams, III, Keith P. Johnston, Jason T. McConville, Jay I. Peters, Robert Talbert, David S. Burgess
-
Patent number: 9687536Abstract: Provided herein are methods for generating dry vaccine powder formulations. Dry vaccine powder formulations can be used for intranasal delivery. Also provided are methods for stimulating local mucosal and systemic immunity by intranasal vaccine delivery.Type: GrantFiled: April 15, 2011Date of Patent: June 27, 2017Assignees: SHIN NIPPON BIOMEDICAL LABORATORIES, LTD., THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTEInventors: Ryoichi Nagata, Shunji Haruta
-
Patent number: 9682038Abstract: Pharmaceutical compositions comprising multi-component crystalline particles suitable for use in inhalation therapy and for delivery by oral or nasal inhalation are provided, wherein said compositions additionally comprise particles of at least one additional active agent. Also provided are methods of preparation of the compositions and their use in medicine.Type: GrantFiled: January 29, 2014Date of Patent: June 20, 2017Assignee: Prosonix LimitedInventors: John Burns, Dipesh Parikh
-
Patent number: 9675629Abstract: The present invention relates to a pH-responsive metal-catechol derivative nanoparticle for drug delivery based on a mussel adhesive protein, particularly Fe(III)-DOPA nanoparticle, and a method for preparing the same. A nanoparticle for drug delivery according to the present invention is prepared using a pH responsive substance, catechol derivative-metal complex, particularly Fe(III)-DOPA complex, based on a mussel adhesive protein. Thereby, the present invention has excellent biocompatibility, is capable of easily and quickly penetrating into a target cell, and releases a loaded drug under acidic conditions, which enables to selectively deliver a drug to a specific disease having an acidic environment.Type: GrantFiled: January 19, 2016Date of Patent: June 13, 2017Assignee: Postech Academy-Industry FoundationInventors: Hyung Joon Cha, Bum Jin Kim, Ho gyun Cheong
-
Patent number: 9643996Abstract: Processes and apparatuses for producing biologically-active, protein-rich microparticles under ambient conditions are disclosed. A protein solution is atomized and collected in a dehydration solvent that is being mixed. The resulting protein microparticles retain high specific activity without the need for large amounts of stabilizing excipients.Type: GrantFiled: November 2, 2012Date of Patent: May 9, 2017Assignee: Battelle Memorial InstituteInventors: Trevor Petrel, Craig Bartling, Lena Furci, Carrie Howland
-
Patent number: 9636350Abstract: The invention relates to a pharmaceutical composition of unit dose for inhalation by a human subject comprising a topical corticoid and a quinolone or fucidic acid, characterized in that the ratio of the weight of the topical corticoid to the weight of the quinolone or fucidic acid is between 0.02 and 20 and the amount of quinolone or of fucidic acid is less than 1 mg. This composition can be administered by nasal spray and is used for treating the upper and lower respiratory tract, in particular sinusitis and nasal polyps.Type: GrantFiled: March 19, 2012Date of Patent: May 2, 2017Inventor: Matthew Krayenbuhl
-
Patent number: 9617582Abstract: A system and method for detecting a biomarker in exhaled breath condensate nanodroplets comprises noninvasively collecting exhaled breath condensate nanodroplets of a subject, and analyzing said nanodroplets utilizing immuno-quantitative polymerase chain reaction to detect one or more target biomarkers.Type: GrantFiled: September 4, 2013Date of Patent: April 11, 2017Assignee: University of Maryland College ParkInventors: Donald K. Milton, Ian M. White
-
Patent number: 9610343Abstract: Viruses, and particularly genetically engineered, replication deficient viruses such as adenoviruses, poxviruses, MVA viruses, and baculoviruses which encode one or more antigens of interest, such as TB, malarial, and HIV antigens, are spray dried with a mannitol-cyclodextrin-trehalose-dextran (MCTD) to form a powder where the viability of the viruses are maintained at a suitable level for mass vaccinations after spray drying, and where the viability of the viruses are maintained at suitable level over a period of storage time, even in the presence of humidity.Type: GrantFiled: May 20, 2010Date of Patent: April 4, 2017Assignee: Aeras Global TB Vaccine FoundationInventors: Tom Han Jin, Eric I-Fu Tsao
-
Patent number: 9585835Abstract: The present invention provides dry powder formulations comprising nicotine, methods of using the same, and methods for making the same. The dry powder formulations may further comprise excipients, therapeutic agents, and flavor components. The dry powder formulations may be manufactured by dry processes and wet processes.Type: GrantFiled: September 16, 2015Date of Patent: March 7, 2017Assignee: Sansa Corporation (Barbados) Inc.Inventors: Alex Stenzler, Noe Zamel, Arthur Slutsky, Steven Ellis
-
Patent number: 9549925Abstract: A system for treating or providing prophylaxus against a pulmonary infection is disclosed comprising: a) a pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition, and b) an inhalation delivery device. A method for providing prophylaxis against a pulmonary infection in a patient and a method of reducing the loss of antiinfective encapsulated in a lipid-based composition upon nebulization comprising administering an aerosolized pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition is also disclosed.Type: GrantFiled: August 19, 2016Date of Patent: January 24, 2017Assignee: INSMED INCORPORATEDInventor: Jeff Weers
-
Patent number: 9549936Abstract: Disclosed are a dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, as pharmaceutically active ingredients, and a carrier, and an inhalation formulation comprising same and a method for preparing the same. The inventive dry powder inhalation formulation having good content uniformity and showing small changes in the aerodynamic size distribution in accordance with the flow rate changes can effectively deliver said pharmaceutically active ingredients to a target site upon administration, and thus can be useful in the prevention or treatment of respiratory diseases, particularly asthma and COPD.Type: GrantFiled: June 22, 2015Date of Patent: January 24, 2017Assignee: HANMI PHARM. CO., LTD.Inventors: Kyeong Soo Kim, Deokkyu Lee, Dong Ho Kim, Yong II Kim, Jae Hyun Park, Jong Soo Woo
-
Patent number: 9545382Abstract: A formulation for treating a patient with hepatocellular carcinoma is disclosed. The formulation comprises therapeutic agents in the form of nanoparticles containing one or more proteins or polysaccharides. The therapeutic agent is conjugated to an active targeting agent causing the formulation to preferentially segregate to the hepatocellular carcinoma tissue to release the therapeutic agents. Methods of treating hepatocellular carcinoma using the formulations are also disclosed.Type: GrantFiled: June 6, 2015Date of Patent: January 17, 2017Assignee: Amrita Vishwa Vidyapeetham UniversityInventors: Manzoor Koyakutty, Giridharan Loghanathan Malarvizhi, Shantikumar Nair
-
Patent number: 9539233Abstract: A method and composition for treatment of bacterial infections caused by gram negative or gram positive bacteria such as Staphylococcus aureus, Rhodococcus equi, Mycobacterium tuberculosis, Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa, using a formulation containing gallium (III), in a pharmaceutically acceptable salt or complex thereof.Type: GrantFiled: May 3, 2010Date of Patent: January 10, 2017Assignee: Aridis Pharmaceuticals Inc.Inventors: Satoshi Ohtake, Vu Truong-Le, David Lechuga-Ballesteros, Luisa Yee, Binh Pham, Russell Martin, Atul Saxena
-
Patent number: 9504742Abstract: Embodiments of the invention are directed to methods of treating, inhibiting or attenuating a microbial infection in an individual who has or is at risk for developing such an infection, comprising the step of administering an effective amount of a StIR composition to the individual.Type: GrantFiled: September 23, 2015Date of Patent: November 29, 2016Assignee: THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Burton Dickey, Michael Tuvim, Scott Evans
-
Patent number: 9491946Abstract: Embodiments of the present disclosure, in one aspect, relate to compositions including a silver/silica nanocomposite, methods of making a silver/silica nanocomposite, methods of using a silver/silica nanocomposite, and the like.Type: GrantFiled: October 31, 2012Date of Patent: November 15, 2016Assignee: University of Central Florida Research Foundation, Inc.Inventors: Swadeshmukul Santra, Roseline Menezes
-
Patent number: 9433576Abstract: The invention relates to respirable dry particles that contain one or more divalent metal cations, such as calcium, in an amount of less than 3% by weight, and to dry powders that contain the respirable particles. The dry particles can further contain an active agent, or can be used as carrier particles to deliver an active agent.Type: GrantFiled: September 29, 2011Date of Patent: September 6, 2016Assignee: Pulmatrix, Inc.Inventors: Michael M. Lipp, Jean C. Sung
-
Patent number: 9415009Abstract: Compositions, methods and systems are provided for pulmonary or nasal delivery of two or more active agents via a metered dose inhaler. In one embodiment, the compositions include a suspension medium, active agent particles, and suspending particles, in which the active agent particles and suspending particles form a co-suspension within the suspension medium.Type: GrantFiled: July 17, 2014Date of Patent: August 16, 2016Assignee: Pearl Therapeutics, Inc.Inventors: Reinhard Vehring, Michael Steven Hartman, David Lechuga-Ballesteros, Adrian Edward Smith, Vidya B. Joshi, Sarvajna Kumar Dwivedi
-
Patent number: 9402918Abstract: A core-shell particle formulation for delivering multiple therapeutic agents is disclosed. More particularly, core-shell particle formulation configured to independently release therapeutic agents from the core and the shell. Moreover, the core-shell particle bearing therapeutic agents enables treatment against the diseases such as cancer, inflammatory and auto-immune diseases.Type: GrantFiled: August 21, 2014Date of Patent: August 2, 2016Assignee: Amrita Vishwa VidyapeethamInventors: Manzoor Koyakutty, Parwathy Chandran, Archana P. R., Shantikumar Nair
-
Patent number: 9394435Abstract: Zwitterionic crosslinking agents, crosslinked zwitterionic hydrogels prepared from copolymerization of zwitterionic monomers with the zwitterionic crosslinking agent, methods for making crosslinked zwitterionic hydrogels, and devices that include and methods that use the crosslinked zwitterionic hydrogels.Type: GrantFiled: August 12, 2014Date of Patent: July 19, 2016Assignee: University of Washington through its Center for CommercializationInventors: Shaoyi Jiang, Hong Xue, Wei Yang, Louisa R. Carr
-
Patent number: 9381152Abstract: The present invention provides an inhalation-type pharmaceutical composition for Parkinson's disease comprising a first gas and an atomized medicine. The first gas comprises hydrogen. The gas volume concentration of hydrogen in the inhalation-type pharmaceutical composition is between 2 to 96%. The atomized medicine is selected from a group comprising levodopa, sinemet, atropine sulfate, scopolamine, dopamine agonist, bromocriptine mesylate, selegiline, carbidopa, entacapone, and any combination thereof. The inhalation-type pharmaceutical composition of the present invention can provide the convenience of taking medicine and removing harmful radicals in the body of the patient through the use of hydrogen while also increases the absorption effect of the medicine for the patient by using an atomized medicine. Therefore, the present invention can provide a treatment for Parkinson's disease that combines the convenience of taking the medicine while also having better curative effects on the user.Type: GrantFiled: March 20, 2015Date of Patent: July 5, 2016Inventor: Hsin-Yung Lin
-
Patent number: 9358318Abstract: The present invention is directed to a reinforced absorbable multilayered hemostatic wound dressing comprising a first absorbable nonwoven fabric, a second absorbable woven or knitted fabric, thrombin and/or fibrinogen.Type: GrantFiled: March 9, 2009Date of Patent: June 7, 2016Assignees: Ethicon, Inc., Omrix Biopharmaceutical, Inc.Inventors: Anne Jessica Gorman, Sanyog Manohar Pendharkar
-
Patent number: 9339459Abstract: The present invention relates to active substances in particulate form, to methods for preparing them and to their uses. The present invention provides particulate powders, such as might be of use for delivery using a dry powder inhaler (DPI) or similar delivery device, having properties which may be beneficial to the DPI delivery process.Type: GrantFiled: September 18, 2012Date of Patent: May 17, 2016Assignee: NEKTAR THERAPEUTICSInventors: Peter York, Boris Yu Shekunov, Mahboob Ur Rehman, Jane Catherine Feeley
-
Patent number: 9339487Abstract: There is provided a dry powder pharmaceutical composition for inhalation useful for preventing and/or treating influenza virus infections contains as a medicinal component a compound represented by formula (I): and optionally a compound represented by formula (II): a pharmacologically acceptable salt thereof, or a hydrate thereof.Type: GrantFiled: December 24, 2009Date of Patent: May 17, 2016Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Makoto Miyajima, Shigeru Noda, Kazuhiro Inoue, Michiko Kumon, Katsuyasu Ishida, Hitoshi Ishizuka
-
Patent number: 9339453Abstract: The present invention provides for an oral serum made from natural ingredients that advantageously reduces oral bacteria. Further, toothpaste and oral rinse compositions are provided. A method for reducing oral bacteria using the oral serum of the present invention is additionally described herein.Type: GrantFiled: November 21, 2012Date of Patent: May 17, 2016Assignee: NOWSystem, Inc.Inventors: Janice Lou King, Dale Leland Winetroub
-
Patent number: 9235814Abstract: Aspects of the present disclosure relate to management of evaluated rule data sets. Specifically, a unreduced evaluated rule data set may contain a number of items to be compared or analyzed according to a number of rules, and may also contain the results of such analysis. An illustrative reduced evaluated data set can include the results of evaluated rules. When utilized in conjunction with an item data set and a rule data set, the information contained within the unreduced evaluated rule data set may be maintained. The reduce memory requirements of the reduced evaluated rule data set may facilitate storage of the reduced evaluated rule data set in faster to access memory, or may facilitate distributed computation of the reduced evaluated rule data set.Type: GrantFiled: August 11, 2014Date of Patent: January 12, 2016Assignee: Amazon Technologies, Inc.Inventors: Jue Wang, Madhu M. Kurup, Jared S. Lundell, Thomas Robert Park
-
Patent number: 9233158Abstract: The present invention is directed toward respirable dry particles for delivery of divalent metal cation salts and/or monovalent cation salts to the respiratory tract and methods for treating a subject having a respiratory disease and/or infection.Type: GrantFiled: May 20, 2015Date of Patent: January 12, 2016Assignee: Pulmatrix, Inc.Inventors: Michael M. Lipp, Jean C. Sung, Robert W. Clarke, David L. Hava